Aisling Capital Management LP
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 13, 2024), Aisling Capital Management LP reported 16 stock positions worth $261.1 million. Its top holding was Bridgebio Pharma (BBIO) at 59.2% of the portfolio, followed by Verona Pharma (VRNA, 12.3%) and Syndax Pharmaceuticals (SNDX, 7.6%). Compared with Q2 2024, it opened 1 new position. The biggest buy was a new position in Bicara Therapeutics (BCAX).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001766721
- Portfolio Value
- $261.1M (Q3 2024)
- SEC Filing
- 0002042586-24-000002 ↗ filed Nov 13, 2024
Holdings Value
Holdings 16 stocks · $261.1M
| BBIO Bridgebio Pharma Inc. | 59.18% | 6,068,125 | $154.5M | No change |
| VRNA Verona Pharma Ltd. | 12.29% | 1,115,352 | $32.1M | No change |
| SNDX Syndax Pharmaceuticals Inc. | 7.56% | 1,025,000 | $19.7M | No change |
| BCAX Bicara Therapeutics Inc. | 5.55% | 568,919 | $14.5M | New |
| BMEA Biomea Fusion Inc. | 3.09% | 798,757 | $8.1M | No change |
| GLUE Monte Rosa Therapeutics Inc. | 2.99% | 1,472,331 | $7.8M | No change |
| CMPS Compass Pathways PLC | 2.33% | 964,500 | $6.1M | No change |
| NUVB Nuvation Bio Inc. | 2.23% | 2,541,009 | $5.8M | No change |
| PSTX Poseida Therapeutics Inc. | 1.14% | 1,043,267 | $3.0M | No change |
| TECX Tectonic Therapeutic Inc. | 0.98% | 84,148 | $2.5M | No change |
| CALC Calcimedica Inc. | 0.88% | 521,114 | $2.3M | No change |
| ELEV Elevation Oncology Inc. | 0.65% | 2,834,910 | $1.7M | No change |
| RENEO PHARMACEUTICALS INC | 0.58% | 886,075 | $1.5M | No change |
| MRKR Marker Therapeutics Inc. | 0.34% | 314,286 | $886K | No change |
| ACRS Aclaris Therapeutics Inc. | 0.19% | 434,455 | $500K | No change |
| VIRX Viracta Therapeutics Inc. | 0.03% | 288,571 | $66K | No change |
Portfolio Sells Q2 2024 → Q3 2024
| None this quarter. | |||
Portfolio Buys Q2 2024 → Q3 2024
| BCAX Bicara Therapeutics Inc. | New | 5.55% | +5.55 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 14 | $471.6M | BBIO, GLUE, SNDX, CMPS, BCAX |
| Q1 2026 | 13 | $476.3M | BBIO, SNDX, GLUE, BCAX, BBOT |
| Q4 2025 | 13 | $478.9M | BBIO, SNDX, GLUE, BCAX, CMPS |
| Q3 2025 | 14 | $456.4M | BBIO, VRNA, SNDX, NUVB, GLUE |
| Q2 2025 | 13 | $359.7M | BBIO, VRNA, SNDX, GLUE, BCAX |
| Q1 2025 | 13 | $288.5M | BBIO, VRNA, SNDX, BCAX, GLUE |
| Q4 2024 | 15 | $281.8M | BBIO, VRNA, SNDX, GLUE, PSTX |
| Q3 2024 | 16 | $261.1M | BBIO, VRNA, SNDX, BCAX, BMEA |
| Q2 2024 | 15 | $231.1M | BBIO, SNDX, VRNA, ELEV, NUVB |
| Q1 2024 | 16 | $295.5M | BBIO, SNDX, VRNA, ELEV, BMEA |